Ignacio Marquez-Gomez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ignacio Marquez-Gomez has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Plata
Infectious Diseases Department, Hospital Universitario Regional de Málaga, Spain
2 shared publications - Beatriz Sobrino
Department of Infectious Diseases, Hospital Regional Universitario Málaga, 29011 Málaga, Spain
2 shared publications - Jose Maria Reguera
Servicio de Enfermedades Infecciosas, Hospital Regional Universitario de Málaga/IBIMA, 29010 Málaga, Spain
2 shared publications - Juan Diego Ruiz-Mesa
IBIMA
2 shared publications - Adrián Montaño
Unidad de Hemostasia y Trombosis, Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain
1 shared publication - Alberto Doblas-Marquez
Unidad de Hemostasia y Trombosis, Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain; (F.J.L.J.); (S.M.-T); (A.D.-M.); (M.I.M.-P.)
1 shared publication
Latest Publications
- Open Access
CLOT STIFFNESS MEASURED BY SEER SONORHEOMETRY AS A MARKER OF POOR PROGNOSIS IN HOSPITALIZED COVID-19 PATIENTS
SUMMARY: Background: High incidence of life-threatening thrombotic complications is observed in severely ill COVID-19 patients. D-dimer may help evaluate disease severity and predict outcomes at hospital admission. However, its non-specificity and long analysis times strongly constrain its clinical value. Viscoelastic tests (VET) are widely available rapid point-of-care devices that have been shown to detect a hypercoagulable state (increased clot stiffness and fibrinolysis shutdown) as major contributors of the thrombotic complication in COVID-19. Nevertheless, based on the data obtained so far, definitive conclusions have not been drawn. Objectives: We aim to evaluate the association between VET parameters, standard coagulation tests and inflammation markers assessed in COVID-19 patients at hospital admission with disease severity and outcomes. Patients/Methods: A total of 69 COVID-19 patients requiring hospitalization were included in the study. The pro-inflammatory and pro-thrombotic state was analyzed by a panel of inflammation markers (IL-6, CRP, LDH, ferritin), routine coagulation tests (PT, aPTT, platelet count, fibrinogen, D-dimer) and a SEER sonorheometry VET profile (Quantra ® System). Results: Inflammatory markers IL-6, CRP, LDH and ferritin were elevated in a high percentage of patients (73.6%, 89.2%, 57.1% and 52.4%), as were coagulation-related parameters such as fibrinogen (81.4%) and D-dimer levels (66.2%). Quantra ® analysis revealed increased clot stiffness (CS) in 34.8%, particularly due to increased fibrinogen contribution (FCS) in 63.7%. Increased clot stability to lysis (CSL) was observed in 32.4%. Age > 65 years, elevated values of fibrinogen, D-dimer, LDH, increased clot stiffness and resistance to clot lysis were significantly associated with worsening disease. The Quantra ® FCS parameter showed a particularly high prognostic value in distinguishing patients with severe symptomatology. Conclusion: The global study of hemostasis by the whole blood point-of-care Quantra ® VET system may be a powerful tool for identifying poor prognosis in COVID-19 patients at hospital admission. In particular, FCS measured by Quantra ® could be established as a plausible prognostic marker to aid the clinical management of COVID-19 patients.
Open AccessCLOT STIFFNESS MEASURED BY SEER SONORHEOMETRY AS A MARKER OF POOR PROGNOSIS IN HOSPITALIZED COVID-19 PATIENTS
SUMMARY: Background: High incidence of life-threatening thrombotic complications is observed in severely ill COVID-19 patients. D-dimer may help evaluate disease severity and predict outcomes at hospital admission. However, its non-specificity and long analysis times strongly constrain its clinical value. Viscoelastic tests (VET) are widely available rapid point-of-care devices that have been shown to detect a hypercoagulable state (increased clot stiffness and fibrinolysis shutdown) as major contributors of the thrombotic complication in COVID-19. Nevertheless, based on the data obtained so far, definitive conclusions have not been drawn. Objectives: We aim to evaluate the association between VET parameters, standard coagulation tests and inflammation markers assessed in COVID-19 patients at hospital admission with disease severity and outcomes. Patients/Methods: A total of 69 COVID-19 patients requiring hospitalization were included in the study. The pro-inflammatory and pro-thrombotic state was analyzed by a panel of inflammation markers (IL-6, CRP, LDH, ferritin), routine coagulation tests (PT, aPTT, platelet count, fibrinogen, D-dimer) and a SEER sonorheometry VET profile (Quantra ® System). Results: Inflammatory markers IL-6, CRP, LDH and ferritin were elevated in a high percentage of patients (73.6%, 89.2%, 57.1% and 52.4%), as were coagulation-related parameters such as fibrinogen (81.4%) and D-dimer levels (66.2%). Quantra ® analysis revealed increased clot stiffness (CS) in 34.8%, particularly due to increased fibrinogen contribution (FCS) in 63.7%. Increased clot stability to lysis (CSL) was observed in 32.4%. Age > 65 years, elevated values of fibrinogen, D-dimer, LDH, increased clot stiffness and resistance to clot lysis were significantly associated with worsening disease. The Quantra ® FCS parameter showed a particularly high prognostic value in distinguishing patients with severe symptomatology. Conclusion: The global study of hemostasis by the whole blood point-of-care Quantra ® VET system may be a powerful tool for identifying poor prognosis in COVID-19 patients at hospital admission. In particular, FCS measured by Quantra ® could be established as a plausible prognostic marker to aid the clinical management of COVID-19 patients.
- Open Access
Clinical and immunoserological status 12 weeks after infection with COVID-19: prospective observational study
Objectives: to undertake a multidisciplinary follow-up at 12 weeks after an acute episode of COVID-19 to assess the functional status, persistence of symptoms and immunoserological situation. Methods: this prospective, observational, single-centre study included outpatients reviewed 12 weeks after an acute infection with SARS-CoV-2. The clinical evaluation included data about the acute episode and epidemiological and clinical variables. The patients were classified as symptomatic or asymptomatic depending on the persistence or otherwise of symptoms. All the patients underwent a full blood test and serology for SARS-CoV-2, as well as imaging tests and spirometry if needed. Results: The mean age of the 108 patients was 55.5 (SD: 15.4) years and 27.8% were health-care workers; 75.9% presented some type of symptoms, with dyspnoea being the most common. A D-dimer >500 ng/mL was detected in 32 (31.4%) patients. All the patients had antibodies against SARS-CoV-2. Being a health-care worker was associated with symptom persistence, with age ≥65 years being a protective factor. Conclusions: The persistence of symptoms in patents with COVID is usual 12 weeks after the acute episode, especially in patients <65 years and health-care workers. All our patients had developed antibodies by 12 weeks.
Open AccessClinical and immunoserological status 12 weeks after infection with COVID-19: prospective observational study
Objectives: to undertake a multidisciplinary follow-up at 12 weeks after an acute episode of COVID-19 to assess the functional status, persistence of symptoms and immunoserological situation. Methods: this prospective, observational, single-centre study included outpatients reviewed 12 weeks after an acute infection with SARS-CoV-2. The clinical evaluation included data about the acute episode and epidemiological and clinical variables. The patients were classified as symptomatic or asymptomatic depending on the persistence or otherwise of symptoms. All the patients underwent a full blood test and serology for SARS-CoV-2, as well as imaging tests and spirometry if needed. Results: The mean age of the 108 patients was 55.5 (SD: 15.4) years and 27.8% were health-care workers; 75.9% presented some type of symptoms, with dyspnoea being the most common. A D-dimer >500 ng/mL was detected in 32 (31.4%) patients. All the patients had antibodies against SARS-CoV-2. Being a health-care worker was associated with symptom persistence, with age ≥65 years being a protective factor. Conclusions: The persistence of symptoms in patents with COVID is usual 12 weeks after the acute episode, especially in patients <65 years and health-care workers. All our patients had developed antibodies by 12 weeks.
- Open Access
- 10 December 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 1-8
Clinical and epidemiological features and prognosis of complicated pyelonephritis: a prospective observational single hospital-based study
Complicated pyelonephritis (cPN), a common cause of hospital admission, is still a poorly-understood entity given the difficulty involved in its correct definition. The aim of this study was to analyze the main epidemiological, clinical, and microbiological characteristics of cPN and its prognosis in a large cohort of patients with cPN. We conducted a prospective, observational study including 1325 consecutive patients older than 14 years diagnosed with cPN and admitted to a tertiary university hospital between 1997–2013. After analyzing the main demographic, clinical and microbiological data, covariates found to be associated with attributable mortality in univariate analysis were included in a multivariate logistic regression model. Of the 1325 patients, 689 (52%) were men and 636 (48%) women; median age 63 years, interquartile range [IQR] (46.5-73). Nine hundred and forty patients (70.9%) had functional or structural abnormalities in the urinary tract, 215 (16.2%) were immunocompromised, 152 (11.5%) had undergone a previous urinary tract instrumentation, and 196 (14.8%) had a long-term bladder catheter, nephrostomy tube or ureteral catheter. Urine culture was positive in 813 (67.7%) of the 1251 patients in whom it was done, and in the 1032 patients who had a blood culture, 366 (34%) had bacteraemia. Escherichia coli was the causative agent in 615 episodes (67%), Klebsiella spp in 73 (7.9%) and Proteus ssp in 61 (6.6%). Fourteen point one percent of GNB isolates were ESBL producers. In total, 343 patients (25.9%) developed severe sepsis and 165 (12.5%) septic shock. Crude mortality was 6.5% and attributable mortality was 4.1%. Multivariate analysis showed that an age >75 years (OR 2.77; 95% CI, 1.35-5.68), immunosuppression (OR 3.14; 95% CI, 1.47-6.70), and septic shock (OR 58.49; 95% CI, 26.6-128.5) were independently associated with attributable mortality. cPN generates a high morbidity and mortality and likely a great consumption of healthcare resources. This study highlights the factors directly associated with mortality, though further studies are needed in the near future aimed at identifying subgroups of low-risk patients susceptible to outpatient management.
- 10 December 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 1-8
Open AccessClinical and epidemiological features and prognosis of complicated pyelonephritis: a prospective observational single hospital-based study
Complicated pyelonephritis (cPN), a common cause of hospital admission, is still a poorly-understood entity given the difficulty involved in its correct definition. The aim of this study was to analyze the main epidemiological, clinical, and microbiological characteristics of cPN and its prognosis in a large cohort of patients with cPN. We conducted a prospective, observational study including 1325 consecutive patients older than 14 years diagnosed with cPN and admitted to a tertiary university hospital between 1997–2013. After analyzing the main demographic, clinical and microbiological data, covariates found to be associated with attributable mortality in univariate analysis were included in a multivariate logistic regression model. Of the 1325 patients, 689 (52%) were men and 636 (48%) women; median age 63 years, interquartile range [IQR] (46.5-73). Nine hundred and forty patients (70.9%) had functional or structural abnormalities in the urinary tract, 215 (16.2%) were immunocompromised, 152 (11.5%) had undergone a previous urinary tract instrumentation, and 196 (14.8%) had a long-term bladder catheter, nephrostomy tube or ureteral catheter. Urine culture was positive in 813 (67.7%) of the 1251 patients in whom it was done, and in the 1032 patients who had a blood culture, 366 (34%) had bacteraemia. Escherichia coli was the causative agent in 615 episodes (67%), Klebsiella spp in 73 (7.9%) and Proteus ssp in 61 (6.6%). Fourteen point one percent of GNB isolates were ESBL producers. In total, 343 patients (25.9%) developed severe sepsis and 165 (12.5%) septic shock. Crude mortality was 6.5% and attributable mortality was 4.1%. Multivariate analysis showed that an age >75 years (OR 2.77; 95% CI, 1.35-5.68), immunosuppression (OR 3.14; 95% CI, 1.47-6.70), and septic shock (OR 58.49; 95% CI, 26.6-128.5) were independently associated with attributable mortality. cPN generates a high morbidity and mortality and likely a great consumption of healthcare resources. This study highlights the factors directly associated with mortality, though further studies are needed in the near future aimed at identifying subgroups of low-risk patients susceptible to outpatient management.